NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) saw a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 6,700,000 shares, an increase of 23.6% from the April 30th total of 5,420,000 shares. Currently, 10.8% of the shares of the stock are sold short. Based on an average trading volume of 993,300 shares, the days-to-cover ratio is presently 6.7 days.

Insider Transactions at NewAmsterdam Pharma

In related news, Director James N. Topper acquired 1,135 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the transaction, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 20.84% of the company's stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its position in NewAmsterdam Pharma by 24.8% during the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock worth $590,000 after purchasing an additional 4,556 shares during the period. American Century Companies Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $8,907,000. Swiss National Bank boosted its position in shares of NewAmsterdam Pharma by 105.1% in the fourth quarter. Swiss National Bank now owns 72,000 shares of the company's stock worth $1,850,000 after buying an additional 36,900 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth about $80,000. Finally, Northern Trust Corp acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $556,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded up $0.04 during trading hours on Thursday, reaching $19.43. 661,015 shares of the company were exchanged, compared to its average volume of 654,215. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -10.33 and a beta of 0.01. The stock has a 50 day simple moving average of $17.76 and a 200 day simple moving average of $20.91. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. On average, analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on NAMS shares. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Needham & Company LLC lowered their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Friday, May 30th. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. Finally, Cantor Fitzgerald assumed coverage on NewAmsterdam Pharma in a research report on Wednesday. They issued an "overweight" rating and a $42.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, NewAmsterdam Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $42.86.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.